Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Retained Earnings (2016 - 2025)

Ironwood Pharmaceuticals' Retained Earnings history spans 16 years, with the latest figure at -$1.1 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 99.94% year-over-year to -$1.1 million; the TTM value through Dec 2025 reached -$1.1 million, up 99.94%, while the annual FY2025 figure was -$1.1 million, 99.94% up from the prior year.
  • Retained Earnings for Q4 2025 was -$1.1 million at Ironwood Pharmaceuticals, up from -$1.7 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $294000.0 in Q1 2025 and bottomed at -$1.7 billion in Q2 2023.
  • The 5-year median for Retained Earnings is -$885.1 million (2021), against an average of -$914.7 million.
  • The largest YoY upside for Retained Earnings was 131.89% in 2025 against a maximum downside of 364053.62% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$937.6 million in 2021, then rose by 25.73% to -$696.4 million in 2022, then tumbled by 143.92% to -$1.7 billion in 2023, then increased by 0.05% to -$1.7 billion in 2024, then soared by 99.94% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Retained Earnings are -$1.1 million (Q4 2025), -$1.7 billion (Q3 2025), and -$1.7 billion (Q2 2025).